ISSN- 2230-7346
*Journal of Global Trends in Pharmaceutical Sciences*

# REGULATORY REQUIREMENT AND CHALLENGES OF MEDICAL DEVICE IN EUROPEAN UNION AND INDIA: A COMPARATIVE STUDY

**G. Hima Bindu, Shaik Nyamathulla*, Y Sarah Sujitha**

Krishna Teja Pharmacy college, Tirupati, Andhra Pradesh, India-517506

**Corresponding author Email:** shaiknyamathulla75@gmail.com

**ARTICLE INFO**

**Key words:**
Medical Device Regulation (MDR)
Conformity Assessment
Clinical Evaluation
Healthcare Innovation
International Standards (ISO, GHTF, IMDRF)

Access this article online
Website: https://www.jgtps.com/
Quick Response Code:

**ABSTRACT**

The global medical device industry is governed by diverse regulatory frameworks that significantly influence product development, approval timelines, market access, and patient safety. This article presents a comprehensive comparative analysis of the regulatory requirements and associated challenges of medical device regulation in the European Union (EU) and India. The EU has implemented the Medical Device Regulation (MDR 2017/745), which replaced the previous Medical Device Directive (MDD), introducing stricter compliance mechanisms, enhanced clinical evaluation requirements, and a centralized database for transparency and traceability (EUDAMED). The regulation emphasizes lifecycle monitoring, vigilance reporting, and the involvement of Notified Bodies for conformity assessments, ensuring a high standard of safety and performance. In contrast, India's regulatory landscape, governed by the Medical Device Rules, 2017 under the Drugs and Cosmetics Act, is still in a transitional phase, evolving to meet international best practices. While India has introduced classification-based risk assessment, licensing requirements, and clinical investigation provisions, several implementation challenges persist, such as inconsistent enforcement, limited regulatory capacity, and the need for harmonization with global standards. This study critically compares the two systems based on regulatory scope, classification systems, conformity assessments, post-market surveillance, and innovation impact. The findings indicate that while the EU provides a robust and mature regulatory system, it also presents significant entry barriers for small and medium-sized enterprises (SMEs) due to high compliance costs and procedural complexity. India, meanwhile, offers a faster entry path but requires further development in regulatory infrastructure and alignment with global standards. The article concludes by proposing strategic recommendations to bridge regulatory gaps, enhance global harmonization, and support safe, timely access to innovative medical devices in both regions.

## INTRODUCTION

The medical device sector is a vital component of modern healthcare systems, contributing to the diagnosis, prevention, monitoring, and treatment of a wide range of medical conditions. As the global demand for advanced and innovative medical technologies grows, regulatory oversight has become increasingly significant in ensuring the safety, efficacy, and quality of these products. Regulatory frameworks not only safeguard public health but also shape the pathways through which manufacturers can access domestic and international markets. Among the key global players, the **European Union (EU)** represents a highly regulated and harmonized market with stringent and

comprehensive legislation under the **Medical Device Regulation (MDR 2017/745)**. Replacing the previous Medical Device Directive (MDD), the MDR introduces rigorous pre- and post-market requirements, increased transparency through centralized databases, and greater oversight of clinical evaluations and conformity assessments. It aims to strengthen patient safety and modernize regulatory oversight in line with technological advancements. In contrast, **India**, one of the fastest-growing medical device markets in Asia, is gradually developing its regulatory framework to align with international standards. Governed by the **Medical Device Rules, 2017** under the **Drugs and Cosmetics Act**, India's approach to regulating medical devices has evolved from a pharmaceutical-centric model to a more device-specific regime. However, challenges such as limited regulatory infrastructure, inconsistent enforcement, and gaps in post-market surveillance persist, particularly given the diversity and volume of devices entering the Indian market. This article presents a comparative study of the regulatory frameworks in the EU and India, with a focus on regulatory classification, approval pathways, conformity assessments, post-market surveillance, and market entry challenges. By analyzing similarities and differences, this study aims to identify opportunities for regulatory harmonization, improved compliance strategies, and enhanced patient safety across jurisdictions.

## DISCUSSION:

### REGULATORY REQUIREMENT EU

- General safety and performance requirements
- Eu declaration of conformity
- Conformity assessment based on a quality management system and on assessment of technical documentation
- Clinical evaluation and post-market clinical follow-up
- Clinical investigation
- Clinical trials
- Registration process

### CDSCO

- Registration of Notified Body
- Documents required for grant of licence to manufacture for sale or for distribution or import
- Quality Management System (QMS) for medical devices
- Post approval change
- Clinical Investigation
- Clinical trial
- Registration process

### GENERAL SAFETY AND PERFORMANCE REQUIREMENTS"

**Intended Performance & Safety:** Medical devices must be designed to perform their intended functions reliably while ensuring the safety of patients, users, and the public. Compliance with latest technical standards is essential to minimize any potential risks during regular operation.

**Comprehensive Risk Management:** Manufacturers are required to implement a continuous risk management process throughout a device's lifecycle. This includes developing detailed risk management plans, systematically identifying and assessing potential hazards, and evaluating Potential risks related to both intended use and predictable misuse. Ongoing adjustments to risk control measures must be made based on insights from production and post-market surveillance[1]

### EU DECLARATION OF CONFORMITY"

**Manufacturer & Identification:** Declaration must include the manufacturer's name, registered trade name or trademark, and, if applicable, it's SRN & details of the authorized representative, along with the registered address.

**Declaration Statement:** It should clearly state that the "EU declaration of conformity" is issued under the sole responsibility of the manufacturer.

**Device Identification:** Document must provide the Basic "UDI-DI", Incorporating the product or trade name, product code or catalog number (or an equivalent identifier), and, when

relevant, a photograph to guarantee precise identification and traceability of the device along with its intended function.

**Risk Classification and Conformity:** It must specify the device's risk class in accordance with Annex VIII and declare that the device conforms with the EU Regulation, as well as Any other applicable EU regulations. References to any harmonised standards (CS) used to demonstrate conformity should also be included.

**Notified Body and Additional Information:** Where applicable, the declaration should mention the notified body's name and identification number, describe the conformity assessment procedure performed, and identify any certificate(s) issued. Any additional relevant information should also be provided.

**Issuance Details:** Finally, the declaration must state the place and date of issue, along with name, function, & signature of the person signing on behalf of the manufacturer[2].

## CONFORMITY ASSESSMENT BASED ON A QUALITY MANAGEMENT SYSTEM AND ON ASSESSMENT OF TECHNICAL DOCUMENTATION"

**Quality Management System (QMS) Requirements:** "Manufacturers are required to establish and maintain a Quality Management System (QMS) in line with Article 10(9)" of the EU Medical Device Regulation (MDR). This framework must comprehensively address key aspects such as risk management, clinical evaluation, post-market surveillance (PMS), and vigilance, ensuring regulatory compliance throughout the product's lifecycle. It should include well-documented policies, procedures, and responsibilities to guarantee both safety and performance.

**Application and Documentation for QMS Assessment:** To undergo QMS assessment, manufacturers must apply through a Notified Body (NB) and provide necessary details, including company information, device classification, a draft EU Declaration of Conformity, and confirmation that no duplicate applications exist. Additional documents, such as risk management plans, PMS procedures, post-market clinical follow-up (PMCF) plans, and clinical evaluation strategies, must also be submitted for review.

**Audit and Certification Process:** The Notified Body conducts an initial audit ofmanufacturer's facilities, including suppliers &subcontractors, to confirm adherence to regulatory standards. Once compliance is verified, an EU QMS Certificate is issued. Manufacturers must report any significant modifications to their QMS or device scope to the NB, which may prompt further audits.

**Surveillance and Ongoing Compliance:** For Class IIa, IIb, and III devices, annual surveillance audits are conducted by the Notified Body, with unannounced audits occurring every five years to ensure continuous regulatory compliance. Random testing of devices is performed, and for Class III devices, additional assessments on material and component integrity are required.

**Consequences of Non-Compliance:** If discrepancies arise between manufactured devices and approved documentation, the Notified Body has the authority to suspend or revoke certification or impose restrictions on production and marketing. Maintaining compliance with EU MDR regulations is essential for continued market approval.[3]

## "CLINICAL EVALUATION AND POST-MARKET CLINICAL FOLLOW-UP"

**Clinical Evaluation Requirements:** Manufacturer must create & maintain a clinical evaluation plan that outlines the safety &performance criteria of a medical device, supported by relevant clinical data. This plan should define the device's intended use, target patient population, expected clinical benefits, and risk-benefit assessment, while also addressing any pharmaceutical or biological aspects if applicable. A systematic literature review must be conducted to assess existing clinical data, identify gaps in evidence, and generate new clinical insights through investigations. The evaluation process should be impartial, considering both positive and negative clinical findings to meet regulatory standards. Additionally, manufacturers may

establish equivalence with other devices based on technical, biological, and clinical similarities, provided they have sufficient access to the necessary data.

**Clinical Evaluation Report & Documentation:** The findings from the clinical evaluation, along with supporting clinical evidence, must be compiled into a Clinical Evaluation Report (CER). This report, along with data from non-clinical testing, forms a critical part of the technical documentation required to prove adherence to general safety and performance standards It should include both favorable and unfavorable clinical data to present a comprehensive and balanced assessment of the device.

**"Post-Market Clinical Follow-Up (PMCF)":** The manufacturer's post-market surveillance plan, PMCF was a continuous process designed to ensure that clinical evaluation remains updated. It involves systematically gathering and analyzing clinical data from CE-marked devices used in real-world setting. The key goals of PMCF are to confirm long-term safety and performance of the device, monitor potential side effects, detect emerging risks, and verify that the benefit-risk ratio continues to be acceptable over time.[4]

**Clinical Investigation in the European Union (EU)** A **clinical investigation** in the European Union is a study conducted on human subjects to assess the safety, performance, and clinical benefits of a medical device. It is essential for obtaining **CE marking** for devices under the **EU Medical Device Regulation (MDR) 2017/745**.

**Regulatory Framework**: Clinical investigations must comply with the **MDR 2017/745** and **Good Clinical Practice (GCP)** standards.

**Approval Process**: Requires approval from an **Ethics Committee** and, in some cases, a **Notified Body**. **Clinical Investigation Plan (CIP)**: Must be created, outlining the study's design, objectives, and risk management.

**Post-Investigation**: Results contribute to the **Clinical Evaluation Report (CER)** and support post-market surveillance efforts, including **Post-Market Clinical Follow-Up (PMCF)**.[5]

**Clinical Trials in the European Union (EU)**

A **clinical trial** in the European Union refers to any systematic study conducted to assess the safety and efficacy of a medical product, typically a pharmaceutical or medical device, in human subjects. Clinical trials are essential for obtaining regulatory approval for products before they are marketed.

**Regulatory Framework**: Clinical trials for medical products are regulated by **EU Clinical Trials Regulation (EU) No. 536/2014** and **EU Medical Device Regulation (MDR) 2017/745** for devices.

**Approval Process**: Trials require approval from an **Ethics Committee** and the **competent national authorities** in each EU member state.

**Key Documents**: A **Clinical Trial Application (CTA)** must be submitted, including trial protocols and informed consent forms.

**Clinical Trial Phases**: Trials are generally conducted in phases (I to IV), starting with small safety trials and moving toward larger, more extensive efficacy trials.

**Good Clinical Practice (GCP)**: Clinical trials must adhere to **Good Clinical Practice (GCP)** standards, ensuring safety, ethical conduct, and data reliability. Clinical trials are essential for generating the evidence required for **CE marking** of medical devices and for regulatory approval of pharmaceutical products in the EU.[6]

**Registration process:** The "European Union Medical Device Regulation (EU MDR 2017/745)" establishes a structured and stringent regulatory framework for medical device within the EU market. It aimto enhance patient safety, improve traceability, and introduce stricter clinical evaluation requirements. Understanding the device registration process under the EU MDR is essential for professionals in regulatory affairs to ensure compliance and successful market approval.

**Classification of "Medical Devices":** Medical devices are categorized based on their risk levels as outlined in Annex VIII of MDR 2017/745

**Conformity Assessment Process:** Conformity assessment procedure varies depending on risk classification of the deviceS:

- **"Class I (Non-Sterile, Non-Measuring)"** → Self-certification by the manufacturer
- **"Class I (Sterile/Measuring), Class IIa, IIb, III**"→ Involvement of a Notified Body (NB) for compliance verification
- **Class III & Implantable Devices** → Undergo rigorous scrutiny with extensive clinical data requirements.[7]

**CDSCO**

**Organizational Documents:**

- Constitution details of the Notified Body.
- Overview of the organization and business profile related to medical device audits.

**Accreditation and Quality Compliance:**

- Accreditation Certificate issued by the National Accreditation Body (as per Rule 11).
- Quality manual of the organization.

**Operational Documentation:**

- List of all Standard Operating Procedures (SOPs).
- List of technical personnel, including external experts, along with their qualifications, experience, and responsibilities.[8]

The **Quality Management System (QMS)** for medical devices, as per **CDSCO** and the **Medical Devices Rules, 2017**, requires manufacturers to comply with **ISO 13485:2016** standards to ensure consistent quality, safety, and performance. It includes documented procedures, risk management, internal audits, and submission of a QMS certificate for import or manufacturing licenses.

**Post-Approval Changes for Medical Devices (CDSCO)** Under the **Medical Devices Rules, 2017**, any **post-approval change** to a medical device—after obtaining an import or manufacturing license—must be **notified to CDSCO** and, in certain cases, requires **prior approval**.

**Types of Post-Approval Changes:**

1. **Administrative Changes** (e.g., change in authorized agent, site address) – usually require notification.
2. **Minor Technical Changes** (e.g., packaging or labeling updates) – may need intimation or justification.
3. **Major Technical Changes** (e.g., change in design, material, intended use) – require **CDSCO approval** before implementation.
4. **Submission Requirements:**

- Submit a **supplementary application** with:

Cover letter explaining the change

Supporting documents (test data, revised labels/manuals, etc.)

Impact assessment on device safety and performance[10]

**Clinical Investigation:** Clinical investigation is conducted to evaluate the effectiveness and safety, to assess the safety, performance, and efficacy of an investigational medical device in human participants. The "Central Licensing Authority (CLA)" oversees the approval process for both clinical investigations and investigational MDs. Clinical performance evaluations using human specimens. These studies adhere to a "Clinical Investigation Plan (CIP) or Clinical Performance Evaluation Plan (CPEP)" to ensure compliance with ethical principles outlined in the Declaration of Helsinki, safeguarding participant rights and safety. Manufacturers seeking to produce a limited quantity of a medical device for clinical testing must submit Form MD-12, including the necessary documentation and associated fees, to CLA. To obtain approval for conducting a clinical investigation, Form MD-22 must be submitted following the same procedure.

**CLINICAL TRIAL:** The forthcoming regulatory framework for clinical trials

involving medical device is developed to enhance efficiency and accelerate approval procedures. While the final version is still under development, key provisions include: (i) a fixed 90-day period for the licensing authority to approve studies; (ii) completion of first subject recruitment within 365 days of approval; (iii) mandatory registration of all clinical investigations with the CTRI before enrolling participants; (iv) academic studies on approved medical devices do not require regulatory approval if endorsed by an Ethics Committee and the data is not intended for marketing purposes; (v) introduction of new study categories su

**REGISTRATION OF MEDICAL DEVICE IN INDIA:** The registration of medical devices in India is governed by the Medical Devices Rules (MDR) 2017, under the oversight of the Central Drugs Standard Control Organization (CDSCO). The regulatory framework aligns with global standards, ensuring safety, efficacy, and quality of medical devices entering the Indian market.

**Regulatory Aspects for Research in Medical Device Registration:** Regulatory Classification and Risk-Based Approach Medical devices are categorized into classification depending on their intended use and the potential risk they pose to patients. Classification determines the level of regulatory scrutiny and clinical evidence required.

**Application Process & Technical Documentation:** Applications are submitted via the **SUGAM online portal** in prescribed forms: **Form MD-1 / MD-7** – For domestic manufacturers. **Form MD-14** – For imported devices. A Device Master File (DMF) and Plant Master File (PMF) are essential for technical evaluation. Higher-risk device required clinical data, risk assessment, and performance evaluations. **Role of Notified Bodies & Clinical Investigations-** Class A & B devices are regulated by Notified Bodies (NBs), while Class C & D require direct approval from CDSCO. Clinical investigations follow Good Clinical Practices (GCP) and require approval through **Form MD-22**. Research studies involving investigational devices must be registered with the CTRI.

**Import & Free Sale Certificate Considerations-** Foreign manufacturers must appoint an Authorized Indian Representative (AIR). Devices with a "Free Sale Certificate (FSC)" from the USA, EU, Japan, Canada, or Australia may qualify for expedited approval without additional clinical trials.

- **Required documents to be submitted with the application for obtaining an Import License or a Manufacturing License for the sale or distribution of a medical device.**

| Category | Documents Required | Applicable to |
|---|---|---|
| General Documents (Class A, B, C, D) | "Device description, intended use, specifications (including variants & accessories) | All applicants |
| | Material of construction | |
| | Working principle & novel technology (if any) | |
| | Labels, package inserts (IFU, user manual) | |
| | Summary of reported Serious Adverse Events & actions taken | |
| | Site or Plant Master File (Appendix I) | |
| | Constitution details of the firm (Domestic Manufacturer/Authorized Agent) | |

| | | |
|---|---|---|
| | Essential Principles Checklist (Safety & Performance) | |
| | Undertaking of compliance with Fifth Schedule | |
| Additional Documents for Import Licence (Class A, B, C, D) | Registration in the country of origin issued by the Competent Authority | Importers |
| | Free Sale Certificate from the National Regulatory Authority (Rule 36) | |
| | Notarized copy of Quality Management System (QMS) Certificate | |
| | Full Quality Assurance Certificate/Production Quality Assurance Certificate | |
| | Self-attested copy of valid Wholesale or Manufacturing Licence | |
| | Latest inspection/audit report from Notified Body/National Regulatory Authority (last 3 years) | |
| Additional Documents for Manufacturing Licence (Class B, C, D) | Device Master File (Appendix II - medical devices, Appendix III - in vitro diagnostic devices | Manufacturers |
| | Test Licence for quality control data generation (if applicable) | |
| | Performance evaluation report (for in vitro diagnostic medical devices)" | |




**Post-Market Surveillance & Compliance**

"Periodic Safety Update Reports (PSURs)" are mandatory for ongoing safety assessment.

Unique Device Identifications (UDI) system ensures better traceability &monitoring.

Regular CDSCO audits and inspection verify compliance with MDR-2017 Regulation as "pivotal" and "pilot" studies, along with the concept of substantial equivalence to existing investigational devices; and (vi) submission of mandatory annual status reports to the licensing authority, including study termination updates and reporting of serious adverse events (SAEs) within 14 days of awareness.[11]

**CONCULSION:**

The **European Union (EU)** and **India (CDSCO)** both enforce comprehensive regulatory frameworks to ensure the **safety, quality, and efficacy** of medical devices. While the **EU Medical Device Regulation (EU MDR 2017/745)** emphasizes **rigorous clinical evaluation**, **post-market surveillance**, and **traceability** through Unique Device Identification (UDI), India's **Medical Devices Rules, 2017 (MDR-2017)** follow a **risk-based classification system**, streamlined through the **SUGAM portal**, and place growing emphasis on **Good Clinical Practices (GCP)**, **QMS compliance (ISO 13485)**, and **vigilance reporting**.

However, both regions face **common challenges**, including:

- Adapting to evolving technologies like AI and software-based devices.
- Ensuring regulatory harmonization and international recognition.
- Managing post-market surveillance and adverse event reporting efficiently.
- Balancing innovation with patient safety and ethical oversight in clinical investigations.

In conclusion, while the **EU MDR** is seen as a global benchmark for stringent regulatory oversight, **India's CDSCO** is rapidly strengthening its framework to align with international norms. For manufacturers and stakeholders, understanding both systems is critical to ensuring timely market access, regulatory compliance, and ultimately, **patient safety and product quality** across global markets.

**REFERENCES:**

1. European Parliament and Council of the European Union. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC. Official Journal of the European Union. 2017 May 5;L117:1–175.

2. European Parliament and Council of the European Union. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC. Official Journal of the European Union. 2017 May 5;L117:1–175. Annex IV.

3. International Organization for Standardization. ISO 14971:2019: Medical devices – Application of risk management to medical devices. Geneva: ISO; 2019..

4. European Commission. MDCG 2020-5: Post-market clinical follow-up (PMCF) of medical devices. Brussels: Medical Device Coordination Group; 2020.

5. International Organization for Standardization. ISO 14155:2020: Clinical investigation of medical devices for human subjects – Good clinical practice. Geneva: ISO; 2020.

6. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH E6(R2): Good Clinical Practice. Geneva: ICH; 2016.

7. European Commission. MDCG 2020-4: Classification of medical devices under the EU MDR. Brussels: Medical Device Coordination Group; 2020.

8. Central Drugs Standard Control Organization (CDSCO). Medical Devices Rules, 2017. New Delhi:

Ministry of Health and Family Welfare, Government of India; 2017 [cited 2025 May 1]. Available from: https://cdsco.gov.in/opencms/opencms/en/Medical-Device-Diagnostics/

9. International Medical Device Regulators Forum (IMDRF). Essential Principles of Safety and Performance of Medical Devices and IVDs. IMDRF/GRRP WG/N47FINAL:2018 [cited 2025 May 1]. Available from: https://www.imdrf.org/documents/essential-principles-safety-and-performance-medical-devices-and-ivds
10. 10.Central Drugs Standard Control Organization (CDSCO). Medical Devices Rules, 2017. New Delhi: Ministry of Health and Family Welfare, Government of India; 2017 [cited 2025 May 1]. Available from: https://cdsco.gov.in/opencms/opencms/en/Medical-Device-Diagnostics/
11. Clinical Trials Registry - India (CTRI). CTRI Guidelines for Registration of Clinical Trials Involving Medical Devices [Internet]. Indian Council of Medical Research; [cited 2025 May 1]. Available from: https://ctri.nic.in